期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Intravitreal triamcinolone acetonide： a ＂real world＂ analysis of visual acuity, pressure and outcomes 被引量：1

Intravitreal triamcinolone acetonide:a "real world" analysis of visual acuity, pressure and outcomes
在线阅读 下载PDF
导出
摘要 Dear Sir,Triamcinolone acetonide（TA）is worldwide available therapeutic agent that is commonly used throughout medicine.TA remains a safe and important ophthalmic therapeutic agent even after the advent of angiogenesis inhibitors[1-2]. Dear Sir,Triamcinolone acetonide（TA）is worldwide available therapeutic agent that is commonly used throughout medicine.TA remains a safe and important ophthalmic therapeutic agent even after the advent of angiogenesis inhibitors[1-2].
作者 Victor Manuel Villegas Aaron Samuel Gold Andrea Wildner Azeema Latiff Timothy Garrett Murray
机构地区 Murray Ocular Oncology and Retina
出处 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2016年第5期789-791,共3页 国际眼科杂志（英文版）
关键词 IOP TA analysis of visual acuity pressure and outcomes real world Intravitreal triamcinolone acetonide
分类号 R774.5 [医药卫生—眼科]
  • 相关文献

参考文献20

  • 1Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138(5):740-743.
  • 2Veritti D, Di Giulio A, Sarao V, Lanzetta P. Drug safety evaluation of intravitreal triamcinolone acetonide. Expert Opin Drug Saf 2012;11(2):331-340.
  • 3Shah NV, Houston SK, Markoe A, Murray TG. Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma. Clin Ophthalmol 2013;7:1877-1882.
  • 4Sawhney GK, Payne JF, Ray R, Mehta S, Bergstrom CS, Yeh S. Combination anti-VEGF and corticosteroid therapy for idiopathic retinal vasculitis, aneurysms, and neuroretinitis syndrome. Ophthalmic Surg Lasers Imaging Retina 2013;44(6):599-602.
  • 5Chen H, Sun S, Li J, Du W, Zhao C, Hou J, Xu Y, Cheng L. Different intravitreal properties of three triamcinolone formulations and their possible impact on retina practice. Invest Ophthalmol Vis Sci 2013;54(3):2178-2185.
  • 6Cabrera M, Gonzalez A, Albini TA, Rowaan C, Aguilar M, Lee W, Fortun JA, Moshfeghi AA, Flynn HW Jr, Parel JM. Differential flow rate of commercially available triamcinolone with and without preservative through small-gauge needles. Ophthalmic Surg Lasers Imaging Retina 2014;45(1):54-57.
  • 7Zacharias LC, Lin T, Migon R, Ghosn C, Orilla W, Feldmann B, Ruiz G, Li Y, Burke J, Kuppermann BD. Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina 2013;33(3):522-531.
  • 8Moshfeghi AA, Nugent AK, Nomoto H, Sanislo SR, Kitchens JW, Moshfeghi DM. Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina 2009;29(5):689-698.
  • 9Spitzer MS, Mlynczak T, Schultheiss M, Rinker K, Yoeruek E, Petermeier K, Januschowski K, Szurman P. Preservative-free triamcinolone acetonide injectable suspension versus "traditional" triamcinolone preparations: impact of aggregate size on retinal biocompatibility. Retina 2011;31(10):2050-2057.
  • 10Albini TA, Abd-El-Barr MM, Carvounis PE, Iyer MN, Lakhanpal RR, Pennesi ME, Chevez-Barrios P, Wu SM, Holz ER. Long-term retinal toxicity of intravitreal commercially available preserved triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48(1):390-395.

同被引文献3

引证文献1

二级引证文献23

International Journal of Ophthalmology(English edition)
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部